Gilead sciences inc(GILD.US AI Earnings Summary)
GILD AI Earnings Summary (In-Depth)
2026 Q3
Core Highlights
HIV and New Products Drive Growth; Full-Year Sales Guidance Raised
- Stock Price Reaction: Gilead Sciences announced its earnings after the bell on October 29, 2026, EST. Driven by an 18% YoY growth in its flagship HIV business, both adjusted EPS and full-year sales guidance outperformed, pushing the stock price up as much as 2.9% to $170.40 in after-hours trading (10/29 EST). During the regular trading session (10/29 EST), the stock closed at $165.61 (+4.03%).
- Market Expectations: Non-GAAP diluted EPS for the quarter was $2.55, beating the market consensus of $2.17 by approximately 17.5%. The significant EPS beat was primarily due to strong sales of the flagship HIV product Biktarvy (up 10% YoY to approx. $4.1B), which drove the overall HIV business up 18% YoY to approx. $6.2B, coupled with effective operating expense management.
- Against Last Quarter's Guidance: During the previous quarter's (2026 Q2) earnings call, only full-year guidance was provided, with no specific guidance for Q3. Therefore, actual Q3 figures cannot be directly compared to full-year guidance. Non-GAAP diluted EPS of $2.55 exceeded the market consensus of $2.17 by approximately 17.5%.
- In One Sentence: Gilead Sciences recorded its fastest base business growth in over a decade this quarter, driven by strong demand for its flagship HIV drug Biktarvy and the new drug Yeztugo, with the market responding with an after-hours surge of up to 2.9%.
The release followed the regular-session close on October 29, 2026. The pre-release close was $165.61; the session’s 4.03% rise preceded the release. On October 30, the first full post-release session, the stock closed at $170.68, up approximately 3.06% from the pre-release close.
Quarterly Highlights
This quarter's Non-GAAP EPS of $2.55 exceeded the market consensus of $2.17 by approximately 17.5%, primarily driven by explosive growth in the HIV business, with the base business recording its strongest YoY growth in a decade.
Base Business Records Strongest Growth in a Decade: 2026 Q3 base business sales (excluding Veklury) reached $8.2B, a 16% YoY increase, the highest growth rate since 2015. Total product sales including Veklury were $8.3B, up 13% YoY and 9% QoQ. Full-year base business sales guidance was raised to $30.7B–$31.0B, an upward revision of approximately $1.65B at the midpoint compared to the initial guidance at the start of the year.
HIV Business Up 18% YoY, Biktarvy Market Share Hits Record High: Total HIV sales reached $6.25B, a YoY increase of nearly $1B, the strongest YoY growth since 2018 Q4, driven by higher average realized price, demand growth, and favorable inventory dynamics. Biktarvy sales were $4.1B, up 10% YoY, with a record 53% share of the US treatment market.
HIV Prevention (PrEP) Business Nearly Doubles, Yeztugo Establishes Market Leadership: PrEP sales nearly doubled YoY, far outperforming the overall US PrEP market growth of 14%. Yeztugo quarterly sales reached $305M, up 31% QoQ, becoming the leading brand for long-acting injectable PrEP in the US, with full-year sales expected to reach approximately $1B. Descovy sales were $1B, up 49% YoY. Together, Yeztugo and Descovy account for 50% of the US PrEP market, with annualized sales reaching $4B.
Trodelvy Up 42% YoY, Reaching $2B Annualized Sales Scale: Trodelvy quarterly sales were $506M, up 42% YoY and 11% QoQ, driven by strong demand in triple-negative and HR+/HER2- metastatic breast cancer, with contributions from both the US and Europe. This quarter also saw European approval for Trodelvy in combination with pembrolizumab for first-line PD-L1 positive metastatic TNBC, further expanding the indications.
Non-GAAP Product Gross Margin Increases to 88%, Operating Margin Maintained at 50%: Gross margin increased by 2 percentage points compared to 86% in 2025 Q3, primarily benefiting from the elimination of TAF-related royalty obligations that expired in November 2025. Non-GAAP operating margin remained at 50%, with Non-GAAP diluted EPS at $2.55. Excluding the one-time contribution of approx. $0.25 per share from IP asset sales in 2025 Q3, EPS grew approximately 15% YoY in real terms.
Livdelzi Up 93% YoY, Liver Disease Business Expands Steadily: Livdelzi (for primary biliary cholangitis, PBC) quarterly sales were $203M, up 93% YoY and 21% QoQ, continuing to consolidate its leadership in the US second-line PBC market. Total liver disease sales reached $927M, up 13% YoY.
IRA Pricing Impact Quantified, 2028 Outlook Remains Positive: The Centers for Medicare & Medicaid Services (CMS) set the Maximum Fair Price for Biktarvy at $2,600 per 30-day supply, a discount of approximately 38% off the list price. Management preliminary estimates the net revenue impact on Biktarvy in 2028 to be approximately $1.5B, but expects total 2028 HIV revenue, total product sales, and EPS to still grow compared to 2027.
Steady Shareholder Returns, Manageable Financial Leverage: In 2026 Q3, approximately $1.4B was returned to shareholders, including $1B in dividends and $370M in share repurchases. Total returns for the first three quarters accounted for approximately 40% of free cash flow. The adjusted debt-to-adjusted EBITDA ratio remained at approximately 1.79x.